* U.S. Food and Drug Administration: Food and Drug Administration Drug Safety Communication: Zofran (ondansetron): Drug Safety Communication—Risk of Abnormal Heart Rhythms. Available at: http:// www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsfor HumanMedicalProducts/ucm272041.htm. Accessed April 9, 2013. An Updated Report by the American Society of Anesthesiologists Task Force on Man...
